



PATIENT NAME : NISHI GUPTA REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID: 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
---	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

BLOOD COUNTS,EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	14.0	12.0 - 15.0	g/dL
METHOD : CYANIDE FREE DETERMINATION			
RED BLOOD CELL (RBC) COUNT	5.48 High	3.8 - 4.8	mil/ μ L
METHOD : ELECTRICAL IMPEDANCE			
WHITE BLOOD CELL (WBC) COUNT	6.50	4.0 - 10.0	thou/ μ L
METHOD : ELECTRICAL IMPEDANCE			
PLATELET COUNT	189	150 - 410	thou/ μ L
METHOD : ELECTRONIC IMPEDANCE			

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	44.6	36 - 46	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	81.0 Low	83 - 101	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	25.6 Low	27.0 - 32.0	pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	31.4 Low	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	16.3 High	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER			
MENTZER INDEX	14.8		
MEAN PLATELET VOLUME (MPV)	10.6	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			

WBC DIFFERENTIAL COUNT

NEUTROPHILS	58	40 - 80	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
LYMPHOCYTES	35	20 - 40	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
MONOCYTES	02	2 - 10	%

Dr. Akansha Jain
Consultant Pathologist



View Details

View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





PATIENT NAME : NISHI GUPTA REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR, 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID: 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
--	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
EOSINOPHILS	05	1 - 6		%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
BASOPHILS	00	0 - 2		%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
ABSOLUTE NEUTROPHIL COUNT	3.77	2.0 - 7.0		thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT	2.28	1.0 - 3.0		thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT	0.13 Low	0.2 - 1.0		thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT	0.32	0.02 - 0.50		thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10		thou/ μ L
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.7			

Interpretation(s)
 BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.
 RBC AND PLATELET INDICES-Mentzer Index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.
 WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.
 [Reference to - The diagnostic and predictive role ofNLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
 This ratio element is a calculated parameter and out ofNABL scope.

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





HC-5726

PATIENT NAME : NISHI GUPTA REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID: 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
---	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C	5.6	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
ESTIMATED AVERAGE GLUCOSE(EAG)	114.0	< 116.0	mg/dL

METHOD : HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
METHOD : CALCULATED PARAMETER

Dr. Akansha Jain
Consultant Pathologist



View Details

View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR, 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID: 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status **Final**

Results

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD

E.S.R 19 0 - 20 mm at 1 hr

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED-FLOW KINETIC ANALYSIS)*

Interpretation(s)

GLYCOSYLATED HEMOGLOBIN(HbA1c), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
- 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c + 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2. Vitamin C & E are reported to falsely lower test results (possibly by inhibiting glycation of hemoglobin).
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD- TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitis, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy ESR in first trimester is 0-48 mm/hr (52 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs (vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology" by Dacie and Lewis, 10th edition.

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID: 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE B

METHOD : TUBE AGGLUTINATION

RH TYPE

POSITIVE

METHOD : TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A, B, O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain
Consultant Pathologist

Page 5 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





PATIENT NAME : NISHI GUPTA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID : 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
--	---	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLUCOSE FASTING,FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) METHOD : GLUCOSE OXIDASE	95	74 - 99	mg/dL
--	----	---------	-------

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : GLUCOSE OXIDASE	115	70 - 140	mg/dL
--	-----	----------	-------

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL METHOD : CHOLESTEROL OXIDASE	183	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
---	-----	--	-------

TRIGLYCERIDES METHOD : LIPASE/GPO-PAP NO CORRECTION	84	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
---	----	---	-------

HDL CHOLESTEROL METHOD : DIRECT CLEARANCE METHOD	42	< 40 Low >/=60 High	mg/dL
--	----	------------------------	-------

CHOLESTEROL LDL METHOD : CALCULATED PARAMETER	124 High	< 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
---	-----------------	--	-------

NON HDL CHOLESTEROL METHOD : CALCULATED PARAMETER	141 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
---	-----------------	--	-------

Dr. Akansha Jain
Consultant Pathologist



[View Details](#) [View Report](#)

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094205912



PATIENT NAME : NISHI GUPTA		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR, 302017 9314660100	ACCESSION NO : 0251XA002187	AGE/SEX : 56 Years Female	DRAWN : 27/01/2024 08:54:00
	PATIENT ID : NISHF231068251	RECEIVED : 27/01/2024 09:31:19	REPORTED : 28/01/2024 09:46:28
	CLIENT PATIENT ID : 012401270013		
	ABHA NO :		

Test Report Status	Final	Results	Biological Reference Interval	Units
VERY LOW DENSITY LIPOPROTEIN		16.8	</= 30.0	mg/dL
CHOL/HDL RATIO		4.4	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO		3.0	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	
Extreme risk group	A. CAD with > 1 feature of high risk group B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <OR = 60)	>OR = 50	>OR = 80

Dr. Akansha Jain
Consultant Pathologist



View Details

View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094205912



PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251XA002187
PATIENT ID : NISHF231068251
CLIENT PATIENT ID : 012401270013
ABHA NO :

AGE/SEX : 56 Years Female
DRAWN : 27/01/2024 08:54:00
RECEIVED : 27/01/2024 09:31:19
REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL METHOD : DIAZO WITH SULPHANILIC ACID	0.55	0 - 1	mg/dL
BILIRUBIN, DIRECT METHOD : DIAZO WITH SULPHANILIC ACID	0.19	0.00 - 0.25	mg/dL
BILIRUBIN, INDIRECT METHOD : CALCULATED PARAMETER	0.36	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD : BIURET REACTION, END POINT	7.9	6.4 - 8.2	g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN	4.5 High	3.8 - 4.4	g/dL
GLOBULIN METHOD : CALCULATED PARAMETER	3.4	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.3	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : TRIS BUFFER NO PSP IFCC / SFBC 37° C	37 High	0 - 31	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : TRIS BUFFER NO PSP IFCC / SFBC 37° C	37 High	0 - 31	U/L
ALKALINE PHOSPHATASE METHOD : AMP OPTIMISED TO IFCC 37° C	96	39 - 117	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : GAMMA GLUTAMYL-3-CARBOXY-4-NITROANILIDE (IFCC) 37° C	23	7 - 32	U/L
LACTATE DEHYDROGENASE	343	230 - 460	U/L

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN METHOD : UREASE KINETIC	12	5.0 - 18.0	mg/dL
--	----	------------	-------

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094205912



PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID : 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CREATININE, SERUM

CREATININE	0.87	0.6 - 1.2	mg/dL
METHOD : ALKALINE PICRATE NO DEPROTEINIZATION			

BUN/CREAT RATIO

BUN/CREAT RATIO	13.79		
METHOD : CALCULATED PARAMETER			

URIC ACID, SERUM

URIC ACID	5.4	2.4 - 5.7	mg/dL
METHOD : URICASE PEROXIDASE WITH ASCORBATE OXIDASE			

TOTAL PROTEIN, SERUM

TOTAL PROTEIN	7.9	6.4 - 8.3	g/dL
METHOD : BIURET REACTION, END POINT			

ALBUMIN, SERUM

ALBUMIN	4.5 High	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL GREEN			

GLOBULIN

GLOBULIN	3.4	2.0 - 4.1	g/dL
----------	-----	-----------	------

ELECTROLYTES (NA/K/CL), SERUM

Dr. Akansha Jain
Consultant Pathologist

Page 9 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR, 302017 9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID : 012401270013

ABHA NO :

AGE/SEX : 56 Years Female
DRAWN : 27/01/2024 08:54:00
RECEIVED : 27/01/2024 09:31:19
REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
SODIUM, SERUM		142.2	137 - 145	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				
POTASSIUM, SERUM		4.30	3.6 - 5.0	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				
CHLORIDE, SERUM		103.4	98 - 107	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenal insufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessive sweating, severe vomiting or diarrhea), diabetes mellitus, diabetes insipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice, oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium-sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO ₃ ⁻), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemia, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in: Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

Decreased in: Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g. galactosemia), Drugs- insulin, ethanol, propranolol, sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.



Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India



Patient Ref. No. 775000004204912



HC-5726

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR, 302017 9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID : 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc. Additional test HbA1c

LIVERFUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in viral hepatitis, Drug reactions, Alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or perniciou anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatase, Malnutrition, Protein deficiency, Wilson's disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

BLOOD UREA NITROGEN (BUN), SERUM- Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of decreased level include Liver disease, SIADH.

CREATININE, SERUM- Higher than normal level may be due to:

* Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscular atrophy

URIC ACID, SERUM- Causes of Increased levels: Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome. Causes of decreased levels: Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM- is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM- Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 77500009820912



HC-5726

PATIENT NAME : NISHI GUPTA REF. DOCTOR : SELF

Table with patient details: CODE/NAME & ADDRESS, AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR, 302017, 9314660100; ACCESSION NO : 0251XA002187; AGE/SEX : 56 Years Female; PATIENT ID : NISHF231068251; DRAWN : 27/01/2024 08:54:00; CLIENT PATIENT ID : 012401270013; RECEIVED : 27/01/2024 09:31:19; ABHA NO : ; REPORTED : 28/01/2024 09:46:28

Test Report Status Final Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40 FEMALE

PHYSICAL EXAMINATION, URINE

Table with 2 columns: Test Name, Result. Includes COLOR (PALE YELLOW), APPEARANCE (SLIGHTLY HAZY)

CHEMICAL EXAMINATION, URINE

Table with 3 columns: Test Name, Result, Reference Range. Includes PH (5.5, 4.7 - 7.5), SPECIFIC GRAVITY (<=1.005, 1.003 - 1.035), PROTEIN (NOT DETECTED, NEGATIVE), GLUCOSE (NOT DETECTED, NEGATIVE), KETONES (NOT DETECTED, NOT DETECTED), BLOOD (NOT DETECTED, NOT DETECTED), BILIRUBIN (NOT DETECTED, NOT DETECTED), UROBILINOGEN (NORMAL, NORMAL), NITRITE (NOT DETECTED, NOT DETECTED), LEUKOCYTE ESTERASE (NOT DETECTED, NOT DETECTED)

MICROSCOPIC EXAMINATION, URINE

Table with 4 columns: Test Name, Result, Reference Range, Units. Includes RED BLOOD CELLS (NOT DETECTED, NOT DETECTED, /HPF), PUS CELL (WBC'S) (2-3, 0-5, /HPF)

Dr. Akansha Jain Consultant Pathologist



View Details View Report

PERFORMED AT : Agilus Diagnostics Ltd, C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road Jaipur, 302015 Rajasthan, India



Patient Ref. No. 775000094205912



HC-5726

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR, 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID : 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
EPITHELIAL CELLS		5-7	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION				
CASTS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
CRYSTALS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
BACTERIA		NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION				
YEAST		NOT DETECTED	NOT DETECTED	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases

Dr. Akansha Jain
Consultant Pathologist



[View Details](#)

[View Report](#)

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912



PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR, 302017
9314660100

ACCESSION NO : 0251XA002187
PATIENT ID : NISHF231068251
CLIENT PATIENT ID: 012401270013
ABHA NO :

AGE/SEX : 56 Years Female
DRAWN : 27/01/2024 08:54:00
RECEIVED : 27/01/2024 09:31:19
REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912



PATIENT NAME : NISHI GUPTA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID : 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
--	---	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD	CONVENTIONAL GYNEC CYTOLOGY
SPECIMEN TYPE	TWO UNSTAINED CERVICAL SMEARS RECEIVED
REPORTING SYSTEM	2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY
SPECIMEN ADEQUACY	SMEARS ARE SATISFACTORY FOR EVALUATION.
MICROSCOPY	SMEARS SHOW PARABASAL, SUPERFICIAL AND INTERMEDIATE SQUAMOUS EPITHELIAL CELLS AGAINST MILD ACUTE INFLAMMATION .ENDO CERVICAL CELLS NOT SEEN , NO DYSPLASIA /MALIGNANCY SEEN.

METHOD : MICROSCOPY
INTERPRETATION / RESULT
 -
 METHOD : MANUAL

NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY
 ATROPHY

Dr. Akansha Jain
Consultant Pathologist



[View Details](#)

[View Report](#)

PERFORMED AT :
 Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India





PATIENT NAME : NISHI GUPTA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID : 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
--	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION,STOOL

COLOUR SAMPLE NOT RECEIVED

METHOD : GROSS EXAMINATION

Dr. Abhishek Sharma
Consultant Microbiologist



[View Details](#)

[View Report](#)

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





HC-5726

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR, 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID : 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

THYROID PANEL, SERUM

T3	102.35	60.0 - 181.0	ng/dL
METHOD : CHEMILUMINESCENCE			
T4	9.30	4.5 - 10.9	µg/dL
METHOD : CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	2.230	0.550 - 4.780	µIU/mL
METHOD : CHEMILUMINESCENCE			

Interpretation(s)

Triiodothyronine T3 , Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level

is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most

of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically

active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1) Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr. Akansha Jain
Consultant Pathologist

Page 17 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India

Patient Ref. No. 775000094209912



HC-5726

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID: 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.
NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

****End Of Report****

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Akansha Jain
Consultant Pathologist

Page 18 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India




Patient Ref. No. 775000094205912

ECG



71467 / MRS NISHI GUPTA / 56 Yrs / F / Non Smoker
Heart Rate : 65 bpm / Tested On : 27-Jan-24 09:37:15 / HF 0.05 Hz - LF 36 Hz / Notch 50 Hz / Sn 1.00 Cm/mV / Sw 25 mm/s
/ Refd By: MADI WHEEL



Vent Rate : 65 bpm
PR Interval : 144 ms
QRS Duration: 86 ms
QT/QTc Int : 378/387 ms
P-QRS-T axis: 12.00° 19.00° 6.00°



Flattened ST segment
Dr. NITIZ GOYAL
MBBS, M.D.
RMC - 023319

Reported By: DR NITIZ GOYAL

NAME	MRS NISHI GUPTA	AGE	58Y	SEX	FEMALE
REF BY	MEDI WHEEL	DATE	27/01/2024	REG NO	

ECHOCARDIOGRAM REPORT

WINDOW- POOR/ADEQUATE/GOODVALVE

MITRAL	NORMAL	TRICUSPID	NORMAL
AORTIC	NORMAL	PULMONARY	NORMAL

2D/M-MOD

IVSD mm	9.5	IVSS mm	13.5	AORTA mm	23.0
LVID mm	35.9	LVIS mm	23.3	LA mm	29.4
LVPWD mm	9.8	LVPWS mm	14.2	EF%	60%

CHAMBERS

LA	NORMAL	RA	NORMAL
LV	NORMAL	RV	NORMAL
PERICARDIUM	NORMAL		

DOPPLER STUDY MITRAL

PEAK VELOCITY m/s E/A	0.93/0.78	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
MVA cm ² (PLANIMETERY)		MVA cm ² (PHT)	
MR			

AORTIC

PEAK VELOCITY m/s	1.18	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
AR			

TRICUSPID

PEAK VELOCITY m/s	1.02	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
TR	TRACE	PASP mmHg	

PULMONARY

PEAK VELOCITY m/s	0.90	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
PR		RVEDP mmHg	

IMPRESSION

- LV DIASTOLIC DYSFUNCTION GRADE-1
- NORMAL LV SYSTOLIC FUNCTION
- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- TRACE TR
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION : DIASTOLIC DYSFUNCTION, LV FUNCTION.

Cardiologist



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com
CIN NO.: U85195RJ2004PTC019563



Name : Ms. NISHI GUPTA

Age/Gender: 56 Y 9 M 4 D/Female

Patient ID : 012401270013

BarcodeNo : 10112996

Referred By : Self

Registration No: 13216

Registered : 27/Jan/2024 08:54AM

Analysed : 27/Jan/2024 11:10AM

Reported : 27/Jan/2024 11:10AM

Panel : ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

OPHTHALMIC VISION TESTING

	RIGHT EYE	LEFT EYE
UCVA	G/36	G/24P
COLOURS	clear	clear
FUNDUS	wnl	wnl

	RIGHT EYE					LEFT EYE				
	SPH	CYL	AXIS	NEAR ADD	AV	SPH	CYL	AXIS	NEAR ADD	AV
PG	-1.00			G/6		-1.25				G/6
ACCEPTANCE	+0.25				N/6	+0.25				N/6
DILATED	←									
ADVISE										

Dr. RAKESH SHARMA
M.S. OPTH & OPTH
FICLLP

*** End Of Report ***

Page 1 of





Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com
CIN NO.: U85195RJ2004PTC019563



Name : Ms. NISHI GUPTA
Age/Gender: 56 Y 9 M 4 D/Female
Patient ID : 012401270013
BarcodeNo : 10112996
Referred By : Self


Registration No: 13216
Registered : 27/Jan/2024 08:54AM
Analysed : 27/Jan/2024 10:25AM
Reported : 27/Jan/2024 10:25AM
Panel : ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

USG: WHOLE ABDOMEN (Female)

- LIVER** : Is normal in size, shape and echogenicity.
The IHBR and hepatic radicals are not dilated.
No evidence of focal echopoor/echorich lesion seen.
Portal vein diameter and Common bile duct normal in size
- GALL BLADDER** : Is not visualized. H/o Cholecystectomy.
- PANCREAS**: Is normal in size, shape and echotexture. Pancreatic duct is not dilated.
- SPLEEN** : Is normal in size, shape and echogenicity. Spleenic hilum is not dilated.
- KIDNEYS** : Right Kidney:-Size: 91 x 36 mm, Left Kidney:-Size: 114 x 42 mm.
Bilateral Kidneys are normal in size, shape and echotexture.
corticomedullary differentiation is fair and ratio appears normal.
Pelvi calyceal system is normal.No evidence of hydronephrosis/ nephrolithiasis.
- URINARY BLADDER** : Bladder walls are smooth, regular and normal thickness.
: No evidence of mass or stone in bladder lumen.
- UTERUS** : Uterus is anteverted with normal in size shape & echotexture.
Uterine muscular shadows normal echopattern.
Endometrium is normal and centrally placed.
No evidence of mass lesion is seen.
- ADNEXA** : Both the ovaries are normal in size shape and echotexture.
No mass lesion/ polycystic ovarian cyst is seen.
- SPECIFIC** : No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.
NO evidence of lymphadenopathy or mass lesion in retroperitoneum.
Visualized bowel loop appear normal.Great vessels appear normal.

IMPRESSION: Ultra Sonography findings are suggestive of: **NORMAL STUDY.**




Dr. Neera Mehta
M.B.B.S., D.M.R.D.
RMCNO.005807/14853



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com
CIN NO.: U85195RJ2004PTC019563

PATIENT NAME: MRS NISHI GUPTA	AGE: 56 Yrs.
REF. by: MEDIWHEEL	DATE: 27/01/2024

Ultrasonography report: Breast and Axilla

Findings:

Right Breast:-

Skin, subcutaneous tissue and retroareolar region is normal.
Fibroglandular tissue shows normal architecture and echotexture.
Pre and retromammary regions are unremarkable.
No obvious cyst, mass or architectural distortion visualized.
Axillary lymphnodes are not significantly enlarged and their hilar shadows are preserved.

Left Breast:-

Skin, subcutaneous tissue and retroareolar region is normal.
Fibroglandular tissue shows normal architecture and echotexture.
Pre and retromammary regions are unremarkable.
No obvious cyst, mass or architectural distortion visualized.
Axillary lymphnodes are not significantly enlarged and their hilar shadows are preserved.

IMPRESSION: No abnormality detected.


DR NEERA MEHTA
MBBS, DMRD
RMCNO.005807/14853



PATIENT NAME : NISHI GUPTA REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID: 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
---	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY - CBC

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

BLOOD COUNTS,EDTA WHOLE BLOOD

HEMOGLOBIN (HB)	14.0	12.0 - 15.0	g/dL
METHOD : CYANIDE FREE DETERMINATION			
RED BLOOD CELL (RBC) COUNT	5.48 High	3.8 - 4.8	mil/ μ L
METHOD : ELECTRICAL IMPEDANCE			
WHITE BLOOD CELL (WBC) COUNT	6.50	4.0 - 10.0	thou/ μ L
METHOD : ELECTRICAL IMPEDANCE			
PLATELET COUNT	189	150 - 410	thou/ μ L
METHOD : ELECTRONIC IMPEDANCE			

RBC AND PLATELET INDICES

HEMATOCRIT (PCV)	44.6	36 - 46	%
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR VOLUME (MCV)	81.0 Low	83 - 101	fL
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	25.6 Low	27.0 - 32.0	Pg
METHOD : CALCULATED PARAMETER			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC)	31.4 Low	31.5 - 34.5	g/dL
METHOD : CALCULATED PARAMETER			
RED CELL DISTRIBUTION WIDTH (RDW)	16.3 High	11.6 - 14.0	%
METHOD : CALCULATED PARAMETER			
MENTZER INDEX	14.8		
MEAN PLATELET VOLUME (MPV)	10.6	6.8 - 10.9	fL
METHOD : CALCULATED PARAMETER			

WBC DIFFERENTIAL COUNT

NEUTROPHILS	58	40 - 80	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
LYMPHOCYTES	35	20 - 40	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY			
MONOCYTES	02	2 - 10	%

Dr. Akansha Jain
Consultant Pathologist



View Details

View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094205912



PATIENT NAME : NISHI GUPTA REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR, 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID: 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
--	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
EOSINOPHILS		05	1 - 6	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
BASOPHILS		00	0 - 2	%
METHOD : IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY				
ABSOLUTE NEUTROPHIL COUNT		3.77	2.0 - 7.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE LYMPHOCYTE COUNT		2.28	1.0 - 3.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE MONOCYTE COUNT		0.13 Low	0.2 - 1.0	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE EOSINOPHIL COUNT		0.32	0.02 - 0.50	thou/ μ L
METHOD : CALCULATED PARAMETER				
ABSOLUTE BASOPHIL COUNT		0 Low	0.02 - 0.10	thou/ μ L
NEUTROPHIL LYMPHOCYTE RATIO (NLR)		1.7		

Interpretation(s)
 BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.
 RBC AND PLATELET INDICES-Mentzer Index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.
 WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.
 [Reference to - The diagnostic and predictive role ofNLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504
 This ratio element is a calculated parameter and out ofNABL scope.

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





HC-5726

PATIENT NAME : NISHI GUPTA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR, 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID : 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
---	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C	5.6	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
ESTIMATED AVERAGE GLUCOSE(EAG)	114.0	< 116.0	mg/dL

METHOD : HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC)
METHOD : CALCULATED PARAMETER

Dr. Akansha Jain
Consultant Pathologist



[View Details](#)

[View Report](#)

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR, 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID: 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status **Final**

Results

Biological Reference Interval Units

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ERYTHROCYTE SEDIMENTATION RATE (ESR),EDTA BLOOD

E.S.R 19 0 - 20 mm at 1 hr

METHOD : AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED-FLOW KINETIC ANALYSIS)*

Interpretation(s)

GLYCOSYLATED HEMOGLOBIN(HbA1c), EDTA WHOLE BLOOD-Used For:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

- 1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.
- 2. eAG gives an evaluation of blood glucose levels for the last couple of months.
- 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c + 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
- 2. Vitamin C & E are reported to falsely lower test results (possibly by inhibiting glycation of hemoglobin).
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.
- 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD- TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculitis, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy ESR in first trimester is 0-48 mm/hr (52 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythemia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs (vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology" by Dacie and Lewis, 10th edition.

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID: 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE B

METHOD : TUBE AGGLUTINATION

RH TYPE

POSITIVE

METHOD : TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A, B, O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain
Consultant Pathologist

Page 5 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094205912



PATIENT NAME : NISHI GUPTA REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID: 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
---	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

BIOCHEMISTRY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

GLUCOSE FASTING,FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)	95	74 - 99	mg/dL
---------------------------	----	---------	-------

METHOD : GLUCOSE OXIDASE

GLUCOSE, POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR)	115	70 - 140	mg/dL
---------------------------------	-----	----------	-------

METHOD : GLUCOSE OXIDASE

LIPID PROFILE WITH CALCULATED LDL

CHOLESTEROL, TOTAL	183	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
--------------------	-----	--	-------

METHOD : CHOLESTEROL OXIDASE

TRIGLYCERIDES	84	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
---------------	----	---	-------

METHOD : LIPASE/GPO-PAP NO CORRECTION

HDL CHOLESTEROL	42	< 40 Low >/=60 High	mg/dL
-----------------	----	------------------------	-------

METHOD : DIRECT CLEARANCE METHOD

CHOLESTEROL LDL	124 High	< 100 Optimal 100 - 129 Near optimal/ above optimal 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
-----------------	-----------------	--	-------

NON HDL CHOLESTEROL	141 High	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
---------------------	-----------------	--	-------

METHOD : CALCULATED PARAMETER

Dr. Akansha Jain
Consultant Pathologist



View Details

View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





PATIENT NAME : NISHI GUPTA		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR, 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID : 012401270013 ABHA NO : :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28	

Test Report Status	Final	Results	Biological Reference Interval	Units
VERY LOW DENSITY LIPOPROTEIN		16.8	</= 30.0	mg/dL
CHOL/HDL RATIO		4.4	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO		3.0	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	

Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

Risk Stratification for ASCVD (Atherosclerotic cardiovascular disease) by Lipid Association of India

Risk Category	
Extreme risk group	A. CAD with > 1 feature of high risk group B. CAD with > 1 feature of Very high risk group or recurrent ACS (within 1 year) despite LDL-C < or = 50 mg/dl or polyvascular disease
Very High Risk	1. Established ASCVD 2. Diabetes with 2 major risk factors or evidence of end organ damage 3. Familial Homozygous Hypercholesterolemia
High Risk	1. Three major ASCVD risk factors. 2. Diabetes with 1 major risk factor or no evidence of end organ damage. 3. CKD stage 3B or 4. 4. LDL >190 mg/dl 5. Extreme of a single risk factor. 6. Coronary Artery Calcium - CAC >300 AU. 7. Lipoprotein a >/= 50mg/dl 8. Non stenotic carotid plaque
Moderate Risk	2 major ASCVD risk factors
Low Risk	0-1 major ASCVD risk factors
Major ASCVD (Atherosclerotic cardiovascular disease) Risk Factors	
1. Age > or = 45 years in males and > or = 55 years in females	3. Current Cigarette smoking or tobacco use
2. Family history of premature ASCVD	4. High blood pressure
5. Low HDL	

Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.

Risk Group	Treatment Goals		Consider Drug Therapy	
	LDL-C (mg/dl)	Non-HDL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Extreme Risk Group Category A	<50 (Optional goal < OR = 30)	< 80 (Optional goal <OR = 60)	>OR = 50	>OR = 80

Dr. Akansha Jain
Consultant Pathologist



View Details

View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251XA002187
PATIENT ID : NISHF231068251
CLIENT PATIENT ID: 012401270013
ABHA NO :

AGE/SEX : 56 Years Female
DRAWN : 27/01/2024 08:54:00
RECEIVED : 27/01/2024 09:31:19
REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Extreme Risk Group Category B	<OR = 30	<OR = 60	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR= 100
Moderate Risk	<100	<130	>OR= 100	>OR= 130
Low Risk	<100	<130	>OR= 130*	>OR= 160

*After an adequate non-pharmacological intervention for at least 3 months.

References: Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

LIVER FUNCTION PROFILE, SERUM

BILIRUBIN, TOTAL METHOD : DIAZO WITH SULPHANILIC ACID	0.55	0 - 1	mg/dL
BILIRUBIN, DIRECT METHOD : DIAZO WITH SULPHANILIC ACID	0.19	0.00 - 0.25	mg/dL
BILIRUBIN, INDIRECT METHOD : CALCULATED PARAMETER	0.36	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD : BIURET REACTION, END POINT	7.9	6.4 - 8.2	g/dL
ALBUMIN METHOD : BROMOCRESOL GREEN	4.5 High	3.8 - 4.4	g/dL
GLOBULIN METHOD : CALCULATED PARAMETER	3.4	2.0 - 4.1	g/dL
ALBUMIN/GLOBULIN RATIO METHOD : CALCULATED PARAMETER	1.3	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE(AST/SGOT) METHOD : TRIS BUFFER NO PSP IFCC / SFBC 37° C	37 High	0 - 31	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT) METHOD : TRIS BUFFER NO PSP IFCC / SFBC 37° C	37 High	0 - 31	U/L
ALKALINE PHOSPHATASE METHOD : AMP OPTIMISED TO IFCC 37° C	96	39 - 117	U/L
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD : GAMMA GLUTAMYL-3-CARBOXY-4-NITROANILIDE (IFCC) 37° C	23	7 - 32	U/L
LACTATE DEHYDROGENASE	343	230 - 460	U/L

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN METHOD : UREASE KINETIC	12	5.0 - 18.0	mg/dL
--	----	------------	-------

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID : 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CREATININE, SERUM

CREATININE	0.87	0.6 - 1.2	mg/dL
METHOD : ALKALINE PICRATE NO DEPROTEINIZATION			

BUN/CREAT RATIO

BUN/CREAT RATIO	13.79		
METHOD : CALCULATED PARAMETER			

URIC ACID, SERUM

URIC ACID	5.4	2.4 - 5.7	mg/dL
METHOD : URICASE PEROXIDASE WITH ASCORBATE OXIDASE			

TOTAL PROTEIN, SERUM

TOTAL PROTEIN	7.9	6.4 - 8.3	g/dL
METHOD : BIURET REACTION, END POINT			

ALBUMIN, SERUM

ALBUMIN	4.5 High	3.8 - 4.4	g/dL
METHOD : BROMOCRESOL GREEN			

GLOBULIN

GLOBULIN	3.4	2.0 - 4.1	g/dL
----------	-----	-----------	------

ELECTROLYTES (NA/K/CL), SERUM

Dr. Akansha Jain
Consultant Pathologist

Page 9 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066
**AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
 AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
 JAIPUR, 302017
 9314660100**

ACCESSION NO : 0251XA002187
PATIENT ID : NISHF231068251
CLIENT PATIENT ID: 012401270013
ABHA NO :

AGE/SEX : 56 Years Female
DRAWN : 27/01/2024 08:54:00
RECEIVED : 27/01/2024 09:31:19
REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
SODIUM, SERUM		142.2	137 - 145	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				
POTASSIUM, SERUM		4.30	3.6 - 5.0	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				
CHLORIDE, SERUM		103.4	98 - 107	mmol/L
METHOD : ION-SELECTIVE ELECTRODE				

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in: CCF,cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy,adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high-dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA,dehydration, overtreatment with saline,hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis,hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide,salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences: Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

Interpretation(s)

GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in:Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in :Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease, malignancy(adrenocortical, stomach,fibrosarcoma),infant of g diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values),there is wide fluctuation within individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.



Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
 C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
 Jaipur, 302015
 Rajasthan, India



Patient Ref. No. 775000094204912



HC-5726

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR, 302017 9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID : 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycaemia, Increased insulin response & sensitivity etc. Additional test HbA1c LIVERFUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in viral hepatitis, drug reactions, alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or perniciou anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatase, Malnutrition, Protein deficiency, Wilson's disease.

GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

BLOOD UREA NITROGEN (BUN), SERUM- Causes of **Increased** levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)

Causes of **decreased** level include Liver disease, SIADH.

CREATININE, SERUM- Higher than normal level may be due to:

* Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to: Myasthenia Gravis, Muscular Dystrophy

URIC ACID, SERUM- Causes of **Increased** levels: Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch-Myhan syndrome, Type 2 DM, Metabolic syndrome. Causes of **decreased** levels: Low Zinc intake, COPD, Multiple Sclerosis

TOTAL PROTEIN, SERUM- is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin.

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM- Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. **Low blood albumin levels (hypoalbuminemia) can be caused by:** Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

Dr. Akansha Jain
Consultant Pathologist

Page 11 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 77500009820912



HC-5726

PATIENT NAME : NISHI GUPTA REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID : 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
--	---	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40 FEMALE

PHYSICAL EXAMINATION, URINE

COLOR	PALE YELLOW
METHOD : GROSS EXAMINATION	
APPEARANCE	SLIGHTLY HAZY
METHOD : GROSS EXAMINATION	

CHEMICAL EXAMINATION, URINE

PH	5.5	4.7 - 7.5
METHOD : DOUBLE INDICATOR PRINCIPLE		
SPECIFIC GRAVITY	<=1.005	1.003 - 1.035
METHOD : IONIC CONCENTRATION METHOD		
PROTEIN	NOT DETECTED	NEGATIVE
METHOD : PROTEIN ERROR OF INDICATORS WITH REFLECTANCE		
GLUCOSE	NOT DETECTED	NEGATIVE
METHOD : GLUCOSE OXIDASE PEROXIDASE / BENEDICTS		
KETONES	NOT DETECTED	NOT DETECTED
METHOD : SODIUM NITROPRUSSIDE REACTION		
BLOOD	NOT DETECTED	NOT DETECTED
METHOD : PEROXIDASE ANTI PEROXIDASE		
BILIRUBIN	NOT DETECTED	NOT DETECTED
METHOD : DIPSTICK		
UROBILINOGEN	NORMAL	NORMAL
METHOD : EHRlich REACTION REFLECTANCE		
NITRITE	NOT DETECTED	NOT DETECTED
METHOD : NITRATE TO NITRITE CONVERSION METHOD		
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
PUS CELL (WBC'S)	2-3	0-5	/HPF
METHOD : DIPSTICK, MICROSCOPY			

Dr. Akansha Jain
Consultant Pathologist



View Details

View Report

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094205912



HC-5726

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR, 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID : 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
EPITHELIAL CELLS		5-7	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION				
CASTS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
CRYSTALS		NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION				
BACTERIA		NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION				
YEAST		NOT DETECTED	NOT DETECTED	

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases

Dr. Akansha Jain
Consultant Pathologist



[View Details](#)

[View Report](#)

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912



PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066
AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR, 302017
9314660100

ACCESSION NO : 0251XA002187
PATIENT ID : NISHF231068251
CLIENT PATIENT ID: 012401270013
ABHA NO :

AGE/SEX : 56 Years Female
DRAWN : 27/01/2024 08:54:00
RECEIVED : 27/01/2024 09:31:19
REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infection when present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

Dr. Akansha Jain
Consultant Pathologist



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India



Patient Ref. No. 775000094204912



PATIENT NAME : NISHI GUPTA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID : 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
--	---	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CYTOLOGY

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PAPANICOLAOU SMEAR

TEST METHOD	CONVENTIONAL GYNEC CYTOLOGY
SPECIMEN TYPE	TWO UNSTAINED CERVICAL SMEARS RECEIVED
REPORTING SYSTEM	2014 BETHESDA SYSTEM FOR REPORTING CERVICAL CYTOLOGY
SPECIMEN ADEQUACY	SMEARS ARE SATISFACTORY FOR EVALUATION.
MICROSCOPY	SMEARS SHOW PARABASAL, SUPERFICIAL AND INTERMEDIATE SQUAMOUS EPITHELIAL CELLS AGAINST MILD ACUTE INFLAMMATION .ENDO CERVICAL CELLS NOT SEEN , NO DYSPLASIA /MALIGNANCY SEEN.

METHOD : MICROSCOPY
INTERPRETATION / RESULT
 -
 METHOD : MANUAL

NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY
 ATROPHY

Dr. Akansha Jain
Consultant Pathologist



[View Details](#) [View Report](#)

PERFORMED AT :
Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





PATIENT NAME : NISHI GUPTA **REF. DOCTOR : SELF**

CODE/NAME & ADDRESS : C000049066 AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN- AAKRITI LABS PVT LTD, A-430, AGRASEN MARG JAIPUR 302017 9314660100	ACCESSION NO : 0251XA002187 PATIENT ID : NISHF231068251 CLIENT PATIENT ID : 012401270013 ABHA NO :	AGE/SEX : 56 Years Female DRAWN : 27/01/2024 08:54:00 RECEIVED : 27/01/2024 09:31:19 REPORTED : 28/01/2024 09:46:28
--	--	--

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

PHYSICAL EXAMINATION,STOOL

COLOUR SAMPLE NOT RECEIVED

METHOD : GROSS EXAMINATION

Dr. Abhishek Sharma
Consultant Microbiologist



[View Details](#)

[View Report](#)

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India





HC-5726

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR, 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID : 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECKUP ABOVE 40FEMALE

THYROID PANEL, SERUM

T3	102.35	60.0 - 181.0	ng/dL
METHOD : CHEMILUMINESCENCE			
T4	9.30	4.5 - 10.9	µg/dL
METHOD : CHEMILUMINESCENCE			
TSH (ULTRASENSITIVE)	2.230	0.550 - 4.780	µIU/mL
METHOD : CHEMILUMINESCENCE			

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyperthyroidism, TSH levels are low.

Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level

is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most

of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically

active. It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3) Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1) Subclinical Hypothyroidism (2) Patient with insufficient thyroid hormone replacement therapy (3) In cases of Autoimmune/Hashimoto thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical inflammation, drugs like amphetamines, Iodine containing drug and dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre (3) Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4 replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism

Dr. Akansha Jain
Consultant Pathologist

Page 17 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India

Patient Ref. No. 775000094209912



HC-5726

PATIENT NAME : NISHI GUPTA

REF. DOCTOR : SELF

CODE/NAME & ADDRESS : C000049066

AGILUS DIAGNOSTICS LIMITED-WEL WALK-IN-
AAKRITI LABS PVT LTD, A-430, AGRASEN MARG
JAIPUR 302017
9314660100

ACCESSION NO : 0251XA002187

PATIENT ID : NISHF231068251

CLIENT PATIENT ID: 012401270013

ABHA NO :

AGE/SEX : 56 Years Female

DRAWN : 27/01/2024 08:54:00

RECEIVED : 27/01/2024 09:31:19

REPORTED : 28/01/2024 09:46:28

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2.Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011.

NOTE: It is advisable to detect Free T3,FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

****End Of Report****

Please visit www.agilusdiagnostics.com for related Test Information for this accession

Dr. Akansha Jain
Consultant Pathologist

Page 18 Of 18



View Details



View Report

PERFORMED AT :

Agilus Diagnostics Ltd.
C/O Aakriti Labs Pvt Ltd, 3, Mahatma Gandhi Marg,Gandhi Nagar Mod, Tonk Road
Jaipur, 302015
Rajasthan, India




Patient Ref. No. 775000094205912

ECG



71467 / MRS NISHI GUPTA / 56 Yrs / F / Non Smoker
Heart Rate : 65 bpm / Tested On : 27-Jan-24 09:37:15 / HF 0.05 Hz - LF 36 Hz / Notch 50 Hz / Sn 1.00 Cm/mV / Sw 25 mm/s
/ Refd By: MADI WHEEL



Vent Rate : 65 bpm
PR Interval : 144 ms
QRS Duration: 86 ms
QT/QTc Int : 378/387 ms
P-QRS-T axis: 12.00° 19.00° 6.00°



Flattened ST segment
Dr. NITIZ GOYAL
MBBS, M.D.
RMC - 023319

Reported By: DR NITIZ GOYAL

NAME	MRS NISHI GUPTA	AGE	58Y	SEX	FEMALE
REF BY	MEDI WHEEL	DATE	27/01/2024	REG NO	

ECHOCARDIOGRAM REPORT

WINDOW- POOR/ADEQUATE/GOODVALVE

MITRAL	NORMAL	TRICUSPID	NORMAL
AORTIC	NORMAL	PULMONARY	NORMAL

2D/M-MOD

IVSD mm	9.5	IVSS mm	13.5	AORTA mm	23.0
LVID mm	35.9	LVIS mm	23.3	LA mm	29.4
LVPWD mm	9.8	LVPWS mm	14.2	EF%	60%

CHAMBERS

LA	NORMAL	RA	NORMAL
LV	NORMAL	RV	NORMAL
PERICARDIUM	NORMAL		

DOPPLER STUDY MITRAL

PEAK VELOCITY m/s E/A	0.93/0.78	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
MVA cm ² (PLANIMETERY)		MVA cm ² (PHT)	
MR			

AORTIC

PEAK VELOCITY m/s	1.18	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
AR			

TRICUSPID

PEAK VELOCITY m/s	1.02	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
TR	TRACE	PASP mmHg	

PULMONARY

PEAK VELOCITY m/s	0.90	PEAK GRADIANT MmHg	
MEAN VELOCITY m/s		MEAN GRADIANT MmHg	
PR		RVEDP mmHg	

IMPRESSION

- LV DIASTOLIC DYSFUNCTION GRADE-1
- NORMAL LV SYSTOLIC FUNCTION
- NO RWMA LVEF 60%
- NORMAL RV FUNCTION
- TRACE TR
- NORMAL CHAMBER DIMENSIONS
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- IVC NORMAL

CONCLUSION : DIASTOLIC DYSFUNCTION, LV FUNCTION.

Cardiologist



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com
CIN NO.: U85195RJ2004PTC019563



Name : Ms. NISHI GUPTA

Age/Gender: 56 Y 9 M 4 D/Female

Patient ID : 012401270013

BarcodeNo : 10112996

Referred By : Self

Registration No: 13216

Registered : 27/Jan/2024 08:54AM

Analysed : 27/Jan/2024 11:10AM

Reported : 27/Jan/2024 11:10AM

Panel : ACROFEMI HEALTHCARE LTD (MEDIWHEEL)

OPHTHALMIC VISION TESTING

	RIGHT EYE	LEFT EYE
UCVA	G/36	G/24P
COLOURS	clear	clear
FUNDUS	wnl	wnl

	RIGHT EYE					LEFT EYE				
	SPH	CYL	AXIS	NEAR ADD	AV	SPH	CYL	AXIS	NEAR ADD	AV
PG	-1.00			G/6		-1.25				G/6
ACCEPTANCE	+0.25					N/6 +0.25				N/6
DILATED	←									
ADVISE										

Dr. RAKESH SHARMA
M.S. OPTH & OPTH
FICLLP

*** End Of Report ***

Page 1 of





Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com
CIN NO.: U85195RJ2004PTC019563



Name : Ms. NISHI GUPTA
Age/Gender: 56 Y 9 M 4 D/Female
Patient ID : 012401270013
BarcodeNo : 10112996
Referred By : Self

Registration No: 13216
Registered : 27/Jan/2024 08:54AM
Analysed : 27/Jan/2024 10:25AM
Reported : 27/Jan/2024 10:25AM
Panel : ACROFEMI HEALTHCARE LTD (MEDIWHEEL)


USG: WHOLE ABDOMEN (Female)

- LIVER** : Is normal in size, shape and echogenicity.
The IHBR and hepatic radicals are not dilated.
No evidence of focal echopoor/echorich lesion seen.
Portal vein diameter and Common bile duct normal in size
- GALL BLADDER** : Is not visualized. H/o Cholecystectomy.
- PANCREAS**: Is normal in size, shape and echotexture. Pancreatic duct is not dilated.
- SPLEEN** : Is normal in size, shape and echogenicity. Spleenic hilum is not dilated.
- KIDNEYS** : Right Kidney:-Size: 91 x 36 mm, Left Kidney:-Size: 114 x 42 mm.
Bilateral Kidneys are normal in size, shape and echotexture.
corticomedullary differentiation is fair and ratio appears normal.
Pelvi calyceal system is normal.No evidence of hydronephrosis/ nephrolithiasis.
- URINARY BLADDER** : Bladder walls are smooth, regular and normal thickness.
: No evidence of mass or stone in bladder lumen.
- UTERUS** : Uterus is anteverted with normal in size shape & echotexture.
Uterine muscular shadows normal echopattern.
Endometrium is normal and centrally placed.
No evidence of mass lesion is seen.
- ADNEXA** : Both the ovaries are normal in size shape and echotexture.
No mass lesion/ polycystic ovarian cyst is seen.
- SPECIFIC** : No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity.
NO evidence of lymphadenopathy or mass lesion in retroperitoneum.
Visualized bowel loop appear normal.Great vessels appear normal.

IMPRESSION: Ultra Sonography findings are suggestive of: **NORMAL STUDY.**

Page 1 of




Dr. Neera Mehta
M.B.B.S., D.M.R.D.
RMCNO.005807/14853



Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod
Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661
www.aakritilabs.com
CIN NO.: U85195RJ2004PTC019563

PATIENT NAME: MRS NISHI GUPTA	AGE: 56 Yrs.
REF. by: MEDIWHEEL	DATE: 27/01/2024

Ultrasonography report: Breast and Axilla

Findings:

Right Breast:-

Skin, subcutaneous tissue and retroareolar region is normal.
Fibroglandular tissue shows normal architecture and echotexture.
Pre and retromammary regions are unremarkable.
No obvious cyst, mass or architectural distortion visualized.
Axillary lymphnodes are not significantly enlarged and their hilar shadows are preserved.

Left Breast:-

Skin, subcutaneous tissue and retroareolar region is normal.
Fibroglandular tissue shows normal architecture and echotexture.
Pre and retromammary regions are unremarkable.
No obvious cyst, mass or architectural distortion visualized.
Axillary lymphnodes are not significantly enlarged and their hilar shadows are preserved.

IMPRESSION: No abnormality detected.


DR NEERA MEHTA
MBBS, DMRD
RMCNO.005807/14853